If you are affected by hepatitis you might be interested in possible examination methods and treatment options.
If you have any questions such as those below you will find some key words in the right column that might be useful for further dialogue:
Taking a small sample of liver tissue by:
Treatment of hepatitis C today is interferon free and based on antiviral combination therapies administered as pills. Treatment duration is usually between 8 or 12 weeks total, tolerability is very good and efficacy in most circumstance >95%. The choice of the regimen depends on HCV Genotype, level of HCV RNA, HCV pretreatment and drug drug interactions with co-medications.
Current regimes of choice are:
For the treatment of hepatitis B two drugs are the preferred treatment options:
Approved are also lamivudine, adefovir and telbivudine, but not considered first choice because of more rapid development of drug resistance. Interferon is an option mainly in HBe-Antigen positive patients with the aim of inducing HBe-Antigen or even HBs-Antigen loss or seroconversion. However interferon is associated with flue like symptoms and other frequent adverse events reducing the quality of life of the patients taking this drug.
It is always an individual decision which drug is chosen for therapy of hepatitis B.
Variables guiding the treatment decision are the level of HIV-DNA, possible pre-treatments, the level of ALT, HBV-genotype and the degree of liver fibrosis. Regular controls to assess the efficacy of therapy are necessary.
To avoid the development of resistance, full suppression of HBV-DNA should be achieved. The development of resistance eliminates the therapeutic effect of the drug used and may lead to cross-resistance to other medications. Immunological control can be induced by hepatitis B therapy resulting in the induction of HBe- or HBs-antibodies. The development of these antibodies can be assessed by laboratory controls. Several months after the development of such antibodies hepatitis B therapy with polymerase inhibitors can be discontinued.
Vaccines against HAV and HBV are available. A vaccination against HBV is recommended for all children and adolescents. A vaccination against HBV protects against HDV. If you are planning to travel into a high-endemic region for viral hepatitis, a vaccination against HAV and HBV is recommended.
|Wirkstoffe & Medikamente||HAV||HBV||HCV||HDV||HEV|